XBiotech Inc. (XBIT)
| Market Cap | 147.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -32.66M |
| Shares Out | 30.48M |
| EPS (ttm) | -1.08 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 324,936 |
| Open | 5.070 |
| Previous Close | 6.380 |
| Day's Range | 3.510 - 5.110 |
| 52-Week Range | 3.510 - 9.960 |
| Beta | 1.34 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2024 |
About XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was inco... [Read more]
Financial Performance
Financial StatementsNews
XBiotech Pauses Rheumatology program
Findings from recently completed Rheumatoid Arthritis Study raise questions Findings from recently completed Rheumatoid Arthritis Study raise questions
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
Tuesday, XBiotech Inc XBIT announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer.
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Bett...
XBiotech: Several Shots On Goal In Big Target Market Indications
XBiotech Inc.'s Hutrukin is being advanced in a phase 1 study to treat reperfusion injury in patients with ischemic stroke. Other studies being deployed are Natrunix for the treatment of patients with...
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and developmen...
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis
(Phase II Multicenter Study is Proceeding Well with High Anticipation) (Phase II Multicenter Study is Proceeding Well with High Anticipation)
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The...
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-con...
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evalu...
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ: XBIT) (“Xbiotech”) announced today that it commenced a “modified Dutch auction” issuer tender offer to purchase up to $80,000,000...
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury a...
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France INCA funded Phase I/II/III Study for Natrun...
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Can...
Why Are XBiotech Shares Trading Higher Today
The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer. The French National Ca...
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France
XBiotech Inks Clinical Manufacturing Deal
XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson XBiotech Manufacturing Antibody Drug for Jansse...
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease Natrunix-SQ, A True Human Antibody Therapy Discovered and...
FDA Approves XBiotech's IND in Rheumatology
Launching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology Launching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology
XBiotech to Launch Novel Candidate Therapy for Stroke
Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New...
XBiotech Announces Payment of Dividend to Holders of Common Stock
Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders
XBiotech Announces Dividend to Holders of Common Stock
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to a...
XBiotech Announces Receipt of $75 Million from Sale of Antibody
Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Infla...
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer
The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Ph...